241 related articles for article (PubMed ID: 18397281)
21. Immunohistochemical differentiation of atypical hyperplasia vs. carcinoma in situ of the breast.
Masood S; Sim SJ; Lu L
Cancer Detect Prev; 1992; 16(4):225-35. PubMed ID: 1281040
[TBL] [Abstract][Full Text] [Related]
22. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
[TBL] [Abstract][Full Text] [Related]
23. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma.
Lehr HA; Folpe A; Yaziji H; Kommoss F; Gown AM
Am J Clin Pathol; 2000 Aug; 114(2):190-6. PubMed ID: 10941333
[TBL] [Abstract][Full Text] [Related]
24. Papillary lesions of the breast: selected diagnostic and management issues.
Collins LC; Schnitt SJ
Histopathology; 2008 Jan; 52(1):20-9. PubMed ID: 18171414
[TBL] [Abstract][Full Text] [Related]
25. [Training and standardized criteria improve the diagnosis of premalignant breast lesions].
Salles Mde A; Gouvêa AP; Savi D; Figueiredo MA; Tavares Neto R; Paula RA; Gobbi H
Rev Bras Ginecol Obstet; 2008 Nov; 30(11):550-5. PubMed ID: 19148432
[TBL] [Abstract][Full Text] [Related]
26. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
Chivukula M; Haynik DM; Brufsky A; Carter G; Dabbs DJ
Am J Surg Pathol; 2008 Nov; 32(11):1721-6. PubMed ID: 18769331
[TBL] [Abstract][Full Text] [Related]
27. Pathology of high-risk breast lesions and ductal carcinoma in situ.
Sewell CW
Radiol Clin North Am; 2004 Sep; 42(5):821-30, v. PubMed ID: 15337418
[TBL] [Abstract][Full Text] [Related]
28. Contemporaneous H&E sections should be standard practice in diagnostic immunopathology.
Hoda SA; Rosen PP
Am J Surg Pathol; 2007 Oct; 31(10):1627. PubMed ID: 17895767
[No Abstract] [Full Text] [Related]
29. [Expression of E-cadherine as a differential diagnostic fest for lobular infiltrative breast cancers].
Chipysheva TA; Ermilova VD; Vishnevskaia IaV; Vasil'ev IuM
Arkh Patol; 2005; 67(6):24-7. PubMed ID: 16405017
[TBL] [Abstract][Full Text] [Related]
30. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
31. [Classification of preinvasive breast and carcinoma in situ: doubts, controversies, and proposal for new categorizations].
Dauplat MM; Penault-Llorca F
Bull Cancer; 2004 Dec; 91 Suppl 4():S205-10. PubMed ID: 15899609
[TBL] [Abstract][Full Text] [Related]
32. Atypical ductal hyperplasia: interobserver and intraobserver variability.
Jain RK; Mehta R; Dimitrov R; Larsson LG; Musto PM; Hodges KB; Ulbright TM; Hattab EM; Agaram N; Idrees MT; Badve S
Mod Pathol; 2011 Jul; 24(7):917-23. PubMed ID: 21532546
[TBL] [Abstract][Full Text] [Related]
33. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias.
Bratthauer GL; Moinfar F; Stamatakos MD; Mezzetti TP; Shekitka KM; Man YG; Tavassoli FA
Hum Pathol; 2002 Jun; 33(6):620-7. PubMed ID: 12152161
[TBL] [Abstract][Full Text] [Related]
34. Squamous cell carcinoma in situ of the breast: a light microscopic and immunohistochemical study of a previously undescribed lesion.
Hayes MM; Peterse JL; Yavuz E; Vischer GH; Eusebi V
Am J Surg Pathol; 2007 Sep; 31(9):1414-9. PubMed ID: 17721198
[TBL] [Abstract][Full Text] [Related]
35. Cytokeratin profiles of male breast cancers.
Ciocca V; Bombonati A; Gatalica Z; Di Pasquale M; Milos A; Ruiz-Orrico A; Dreher D; Folch N; Monzon F; Santeusanio G; Perou CM; Bernard PS; Palazzo JP
Histopathology; 2006 Oct; 49(4):365-70. PubMed ID: 16978199
[TBL] [Abstract][Full Text] [Related]
36. Atypia on breast core needle biopsies: reproducibility and significance.
Darvishian F; Singh B; Simsir A; Ye W; Cangiarella JF
Ann Clin Lab Sci; 2009; 39(3):270-6. PubMed ID: 19667411
[TBL] [Abstract][Full Text] [Related]
37. [Management of ductal carcinoma in situ by the pathologist: current questions].
Arnould L; Caron Y; Sigal-Zafrani B
Ann Pathol; 2003 Dec; 23(6):534-46. PubMed ID: 15094591
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay.
Yu Q; Niu Y; Yu Y; Ding X; Shi Y
Breast Cancer Res Treat; 2009 Apr; 114(3):433-40. PubMed ID: 18425676
[TBL] [Abstract][Full Text] [Related]
39. Predicting cancer on excision of atypical ductal hyperplasia.
Doren E; Hulvat M; Norton J; Rajan P; Sarker S; Aranha G; Yao K
Am J Surg; 2008 Mar; 195(3):358-61; discussion 361-2. PubMed ID: 18206849
[TBL] [Abstract][Full Text] [Related]
40. Proliferative lesions of the breast: carcinoma in situ.
Chinoy RF
Indian J Pathol Microbiol; 2003 Apr; 46(2):153-64. PubMed ID: 15022899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
